Harding Loevner’s Bristol-Myers Squibb BMY Stock Holding History

Harding Loevner’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,086	Closed	-$77K	–	94
2022 Q3	$77K	Hold	1,086	–	–	﹤0.01%	92
2022 Q2	$84K	Hold	1,086	–	–	﹤0.01%	89
2022 Q1	$83K	Sell	1,086 -382	-26%	-$25.6K	﹤0.01%	88
2021 Q4	$92K	Buy	+1,468	New	+$86.1K	﹤0.01%	95
2017 Q3	–	Sell	-780	Closed	-$43K	–	129
2017 Q2	$43K	Buy	+780	New	+$42.4K	﹤0.01%	102

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Harding Loevner's BMY Position: Q4 2022 in Review

Harding Loevner sold out of Bristol-Myers Squibb (BMY) in Q4 2022, closing a stake of 1,086 shares — an estimated $77K sold.

Harding Loevner first reported a position in BMY in Q2 2017 and held it in 5 quarters. The position peaked at $92K in Q4 2021. 2,602 funds tracked by Wall St. Rank hold BMY as of Q4 2022.

Harding Loevner reported no remaining Bristol-Myers Squibb position as of Q4 2022 after selling out during the quarter.
Harding Loevner sold 1,086 Bristol-Myers Squibb shares in Q4 2022, an estimated $77K.
Harding Loevner first reported a position in Bristol-Myers Squibb in Q2 2017 and held it in 5 quarters.
Harding Loevner's Bristol-Myers Squibb position peaked at $92K in Q4 2021.
2,602 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2022.

Based on Harding Loevner's 13F filing for Q4 2022, filed 14 Feb 2023.